Subscribe
shutterstock_1862407378_ralf_liebhold
Ralf Liebhold / Shutterstock.com
17 March 2022AmericasMuireann Bolger

Teva can pursue migraine patent dispute against Eli Lilly

Eli Lilly has failed to convince a US judge to toss a patent infringement lawsuit filed by Teva Pharmaceuticals in a dispute over a migraine medication.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Eli Lilly secures trade secret suit dismissal
27 September 2022   Pharma firm beats back digital health company over migraine tracking app / Indiana’s Uniform Trade Secrets Act cited by US judge.
Big Pharma
Eli Lilly avoids sanctions in Teva migraine treatment dispute
13 January 2022   Teva Pharmaceuticals has failed to persuade a federal judge in Massachusetts that Eli Lilly should be penalised over its discovery search related to a patent dispute concerning a migraine treatment.
Big Pharma
Eli Lilly can’t avoid royalties in insulin suit
21 October 2021   Eli Lilly will have to pay undetermined royalties from the net sale of its diabetes treatment to Research Corporation Technologies, an Arizona judge has ruled.


Editor's picks

Smart ringleader: Could Ōura’s market dominance be under threat?
Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025

Editor's picks

Americas
Smart ringleader: Could Ōura’s market dominance be under threat?
5 September 2025
Europe
Sandoz blocked by UK court from seeking Xarelto profits
2 September 2025
Europe
UPC sees rising small molecule litigation with Pfizer in the hot seat
29 August 2025
Europe
Astellas win strengthens blockbuster drug's European position
20 August 2025
Europe
Four firms reach highest tier in WIPR’s 2025 Global Trade Secrets Rankings
18 August 2025
Americas
Latham steps into dispute over $6bn treatment, replacing Kirkland
13 August 2025

More on this story

Americas
Eli Lilly secures trade secret suit dismissal
27 September 2022   Pharma firm beats back digital health company over migraine tracking app / Indiana’s Uniform Trade Secrets Act cited by US judge.
Big Pharma
Eli Lilly avoids sanctions in Teva migraine treatment dispute
13 January 2022   Teva Pharmaceuticals has failed to persuade a federal judge in Massachusetts that Eli Lilly should be penalised over its discovery search related to a patent dispute concerning a migraine treatment.
Big Pharma
Eli Lilly can’t avoid royalties in insulin suit
21 October 2021   Eli Lilly will have to pay undetermined royalties from the net sale of its diabetes treatment to Research Corporation Technologies, an Arizona judge has ruled.

More on this story

Americas
Eli Lilly secures trade secret suit dismissal
27 September 2022   Pharma firm beats back digital health company over migraine tracking app / Indiana’s Uniform Trade Secrets Act cited by US judge.
Big Pharma
Eli Lilly avoids sanctions in Teva migraine treatment dispute
13 January 2022   Teva Pharmaceuticals has failed to persuade a federal judge in Massachusetts that Eli Lilly should be penalised over its discovery search related to a patent dispute concerning a migraine treatment.
Big Pharma
Eli Lilly can’t avoid royalties in insulin suit
21 October 2021   Eli Lilly will have to pay undetermined royalties from the net sale of its diabetes treatment to Research Corporation Technologies, an Arizona judge has ruled.

More features

GSK escalates mRNA COVID-19 vaccine dispute
Smart ringleader: Could Ōura’s market dominance be under threat?
The flaw that landed Sanofi a win in the rare disease space
Roche resolves cancer test dispute with Stanford affiliated startup
Why Masimo’s ‘rare’ move pushes Apple case into uncharted territory
UK firm expands in Germany with more litigation hires
Sandoz blocked by UK court from seeking Xarelto profits
The rise of pro-NPE and patent sentiment in the US